Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2014

View Archived Issues

Phase II results for the influenza A/H7N9 vaccine in combination with an adjuvant

Shionogi recaps highlights of second quarter of fiscal 2014

Novel genetic biomarkers of human malformation disorders

Sumitomo Dainippon Pharma reviews second quarter of fiscal 2014

Sanofi presents highlights of third quarter 2014

Researchers present novel targets and biomarkers in pancreatic cancer

FDA orphan drug status granted to oprozomib for multiple myeloma

Sodium thiosulfate designated orphan drug by the FDA

Glioma candidate pritumumab receives U.S. orphan drug designation

MPDL-3280A well tolerated in phase Ia trial in patients with mRCC

EMA publishes revised guideline on biosimilars

EMA releases third and final module on influenza vaccine guidance for public consultation

Chugai licenses EpiVax de-immunization technologies to optimize biologics pipeline

Swiss approval to begin Ebola vaccine trial

Award supports Verona Pharma's exploration of RPL-554 for cystic fibrosis

New PDE4B inhibitors reported by Gruenenthal

Esteve presents novel ligands of sigma receptors

Guangzhou Baiyunshan Pharmaceutical synthesizes tricyclic quinolones

Canadian company presents CRP40 fragments for neurological disorders

Glenmark Pharmaceuticals reports novel mPGES-1 inhibitors

New GnRH receptor antagonists discovered at Bayer Schering Pharma

Salix and Pharming launch Ruconest in the U.S. for acute angioedema attacks in HAE

Novartis plans phase I/II trial of Wnt-targeting drug regimen in BRAF-mutant colorectal cancer

Arena Pharmaceuticals to test APD-811 in patients with pulmonary arterial hypertension

Nymox's NX-1207 fails to achieve efficacy endpoints in phase III BPH trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...